Baird Financial Group Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baird Financial Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,713 shares of the biopharmaceutical company's stock after selling 1,135 shares during the period. Baird Financial Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $24,727,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Willner & Heller LLC raised its holdings in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after acquiring an additional 15 shares in the last quarter. OLD Second National Bank of Aurora raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. UBS Group reduced their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Bernstein Bank reduced their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Guggenheim lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $892.60.

Regeneron Pharmaceuticals Stock Down 0.3 %

REGN stock opened at $603.58 on Tuesday. The firm's 50-day moving average is $624.42 and its two-hundred day moving average is $704.67. The company has a market capitalization of $65.99 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.